Have Therapeutics Enhanced Our Knowledge of Axial Spondyloarthritis?

S R Harrison, H Marzo-Ortega

Current rheumatology reports 2023 Mar

filter terms:

An overview of how the treatment landscape of axial spondyloarthritis (axSpA) has shaped our understanding of the disease. Prior to the millennium, non-steroidal anti-inflammatory drugs (NSAIDs) were the only treatment for axSpA, yet only 30% of patients responded and many developed side effects. In 2003, the first biological disease-modifying drug (bDMARD) was licensed for axSpA which substantially improved outcomes in comparison to NSAIDs. In 2022, there are now several bDMARDs for axSpA; however, they too are not universally efficacious in treating axial inflammation and may have deleterious effects on extramusculoskeletal manifestations. Nevertheless, successful or not, each bDMARD gives invaluable insight into axSpA immunobiology. This review discusses how much we have learned from the use of bDMARDs in axSpA, how this has redefined our understanding of the disease, and how we might use this knowledge to develop new and better treatments for axSpA in the future. © 2023. The Author(s).

Citation

S R Harrison, H Marzo-Ortega. Have Therapeutics Enhanced Our Knowledge of Axial Spondyloarthritis? Current rheumatology reports. 2023 Mar;25(3):56-67